Sort
30,917 grants matching “tumor microenvironment”
IGF::OT::IGF SBIR Topic 355: A 3D Perfusable Platform for HTS Across Diverse Racial/Ethnic Cancer Specimens To generate racially diverse patient-derived xenograft (PDX)-derived prostate cancer culture
$297,962Anthony Saleh · Mimetas Us, Inc. · N43 · FY2017 · CA
Mitochondrial ROS, Aging and Cancer
$297,921Warren C. Ladiges · University Of Washington · P01 · FY2011 · AG
Ephrin-A1 in Tumor-Endothelial Interaction During Metastasis
$297,896Jin Chen · Vanderbilt University · R01 · FY2009 · CA
Development of a Novel, Plasma-Based Microsatellite Instability Diagnostic for Guiding Immunotherapy
$297,850Mark Sausen · Personal Genome Diagnostics, Inc. · R43 · FY2017 · CA
The Impact of PD-1 Inhibition on Immune-Response to Chemoradiotherapy
$297,829Steven Francis Powell · Sanford Research/Usd · P20 · FY2016 · GM
The Impact of PD-1 Inhibition on Immune-Response to Chemoradiotherapy
$297,828Steven Francis Powell · Sanford Research/Usd · P20 · FY2017 · GM
A Phase I safety & immunogenicity study of an HPV16-specific therapeutic protein, TA-CIN, administered intratumorally with chemoradiation in patients with cervical cancer stratified by HPV16 infection
$297,816T.-C. Wu · Johns Hopkins University · P50 · FY2023 · CA
ADHESION AND ERK SIGNALING IN MELANOMA
$297,794Andrew E Aplin · Thomas Jefferson University · R01 · FY2010 · GM
Computer-based assessment of tumor microenvironment (TME) in Follicular Lymphoma
$297,785Metin Nafi Gurcan · Ohio State University · R01 · FY2015 · CA
Fibroblast Activation Protein in the Tumor Microenvironment in Lung Cancer
$297,775Ellen Pure' · University Of Pennsylvania · R01 · FY2014 · CA
RON Receptor in Pancreatic Cancer Biology and Therapy
$297,734Andrew M Lowy · University Of California, San Diego · R01 · FY2019 · CA
Targeted delivery of a VEGFâblocking scFv by CD70 CARâT cells to enhance antiâtumor activity in renal cell carcinoma
$297,728Mark Leick · Massachusetts General Hospital · K08 · FY2025 · CA
Targeted delivery of a VEGFâblocking scFv by CD70 CARâT cells to enhance antiâtumor activity in renal cell carcinoma
$297,728Mark Leick · Massachusetts General Hospital · K08 · FY2024 · CA
Glioblastoma tumor microenvironmental influence on acquired and inherent cancer therapy resistance.
$297,715Christopher D Willey · University Of Alabama At Birmingham · U01 · FY2020 · CA
Biomarker-Driven Src Inhibitor Studies in Colorectal Cancer Patients
$297,680Wells A Messersmith · University Of Colorado Denver · R01 · FY2010 · CA
Polymers for Targeted Delivery of Angiogenic Inhibitors
$297,654Hamid Ghandehari · University Of Utah · R01 · FY2009 · EB
Development of Angiogenesis Inhibitors
$297,586William Douglas Figg · Division Of Clinical Sciences - Nci · ZIA · FY2011 · CA
Mechanisms of immunomodulation with epigenetic therapy
$297,559Nilofer S. Azad · Johns Hopkins University · P01 · FY2024 · CA
The Molecular Profile of Prostate Tumors in African-American Men
$297,523Stefan Ambs · Division Of Basic Sciences - Nci · ZIA · FY2014 · CA
Anticancer Strategies Targeting the Autotaxin-LPA Receptor Axis
$297,491Gabor J Tigyi · University Of Tennessee Health Sci Ctr · R01 · FY2016 · CA
Anticancer Strategies Targeting the Autotaxin-LPA Receptor Axis
$297,491Gabor J Tigyi · University Of Tennessee Health Sci Ctr · R01 · FY2015 · CA
Regulation of Quiescence in Eukaryotic Cells
$297,487David Gresham · New York University · R01 · FY2017 · GM
Therapeutic anti-angiogenesis and tumor microenvironment
$297,485University Of California Los Angeles · R01 · FY2005 · CA
Correction of myeloid cell defects in cancer
$297,480Dmitry Isaac Gabrilovich · Wistar Institute · R01 · FY2014 · CA
Peroxisome Proliferator-Activated Receptor (gamma) in Lung Cancer
$297,398Raphael A. Nemenoff · University Of Colorado Denver · R01 · FY2012 · CA